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 Under the cooperation between Atomic Bomb Disease 
Institute (ABDI) of Nagasaki University School of Medicine, 
Institute of Nuclear Medicine of Hiroshima University and 
Radiation Effect Research Foundation (RERF), the Life 
Span Study (LSS) on 93,741 survivors (fixed cohort) and the 
Open City Study (OCS) on all survivors (unfixed) irrespec-
tive of whether they belonged to LSS or not, have been 
conducted in parallel over 45 years to ensure reliable case 
detection. For diagnosis and subtyping of detected 
leukemias, we adopted the FAB classifcation for acute 
leukemias and for exposure dose of individual survivors, the 
new dosimetry system 1986 (DS86). 
 In LSS, 231 leukemia cases were analysed. There was 
strong evidence of radiation-induced risks for acute myeloid 
leukemia (AML), acute lymphoid leukemia (ALL) and 
chronic myeloid leukemia (CML), but not for adult T-cell 
leukemia (an endemic disease in Nagasaki area) and chronic 
lymphocytic leukemia. There was also significant difference 
between three major types with respect to the effects of age at 
bombing and sex, and in the temporal pattern of the elevated 
risks. For AML the dose response function was non-linear, 
whereas there was no evidence against linearity for ALL and 
CML. The hypothesis of a 0.5 Gy threshold could be rejected 
for three major types of leukemia. Excess Absolute Risk 
(EAR) estimates in cases per 10,000 Person Year Sievert 
(PYSv) were 0.6, 1.1, 0.9 for ALL, AML and CML, respec-
tively. The corresponding relative risk at 1.0 Sv were 9.1, 3.3, 
6.2, respectively. Although childhood exposure <15 age at 
bombing apparently induced three major types, the age-
related highest risk was observed for ALL. 
 In OCS, 413 cases with DS86 estimates were used for analy-
sis. Type specific incidence rates were calculated indirectly 
by using the over all incidence of leukemia from LSS data 
and multiplying these values by the corresponding propor-
tions of cases in OCS. In conjunction with LSS data, the 
effects of radiation were significantly greater on the 
incidences of ALL and CML than on that of AML. In the high 
dose group there was a strong evidence for shorter incubation 
time and faster decline of elevated risk for ALL and CML 
than for AML. AML risk was apparently persistent through 
1980. 
 Thus, the differential effects of atomic bomb irradiation in 
inducing three major types of leukemia with respect of 
age-related and temporal patterns provide us insights into 
human leukemogenesis. Further investigation on radiation 
leukememogenesis undoubtedly requires molecular ap-
proach to detect type-specific genetic abnormlities including 
oncogenes and anti-oncogenes.
Introduction 
 Close relation between radiation exposure and leukemia 
induction has been well known since the discovery and 
clinical use of X ray by Roentgen in 1895, a hundred years 
ago. It passed 50 years after this discovery to the use of 
atomic bombs in war in 1945. During this period, hazards 
from exposure to radiation were fequently reported ; 
among them the most important was the leukemia occur-
rence among English patients with anchylosing spondylitis 
treated with large doses of radiation'). Therefore, it could 
be suspected that leukemia induction would be observed 
among atomic bomb survivors of Hiroshima and 
Nagasaki. 
  A few years after the atomic bombs physicians in both 
cities simultaneously began to notice an increased number 
of patients with leukemia. Under the supervision of former 
Atomic Bomb Causalty Commission (ABCC) a large 
cohort study named Leukemia Detection Program (HE39) 
was started in 1950. Within a decade it was statistically 
confirmed that atomic bomb irradiation actually induced 
an increased risk of leukemia among heavily exposed 
survivors 2). Thus it became a common knowledge for a 
physician that radiation can cause leukemia. All textbooks 
of hematology now contain a description about atomic 
bomb irradiation-induced leukemia. However, it still 
remains unsolved what molecular or genetic events induce 
leukemia in blood cells. 
 Leukemia is a relatively rare disease accounting only 4 % 
of the cancer deaths in the Radiation Effect Research 
Foundation (RERF)'s fixed Life Span Study (LSS) cohort. 
However, leukemia is estimated to be accounted for 20% 
of the excess cancer deaths in this cohort, suggesting its 
remarkablly high relative risk among all cancers. In order 
to better understand biological significance of Atomic 
Bomb-induced leukemias in the context of human 
leukemogenesis we have analysed comprehensive data 
obtained from two types of long term leukemia detection 
programs conducted over 45 years.
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Epidemiology of leukemia among atomic bomb 
survivors 
(1) Study Design and Cohort 
 Since 1950 we have conducted two types of leukemia 
detection program : one is the leukemia registration for 
the 120,321 persons of RERF's Life Span Study (LSS) 
cohort consisting of 93,741 survivors who were in either 
city at the time of the bombings (ATB)3' and 26,580 
control cases who were not in either city ATB, and another 
is the Open City Study (OCS) in which all leukemia cases 
occurring among survivors who were within 9 km of the 
hypocenter in either city ATB were registered irrespective 
of whether they belonged to LSS cohort or not'). The LSS 
Study was planned for the formal RERF's statistical 
analysis for diseases induced by atomic bomb irradiation 
and the OCS for the most reliable leukemia case-detection 
among many hospitals in Hiroshima and Nagasaki. The 
total number of the OCS Sample is not known but roughly 
three fold larger than that of LSS cohort as shown in Fig 
1. Each case occuring from outside LSS cohort was care-
fully confirmed for residency at bombing and exposure 
dose was estimated exactly in the same way as in LSS 
Study.
(3) Leukemia classification 
 The previous reports of LSS from RERF employed a 
rather old classification basically derived from Wintrobe's 
textbook of hematology. The present comprehensive LSS 
report incorporated an up-dated classification system as 
employed in the leukemia reclassification study on OCS 
Sample (RERF technical report 9-91) in order to improve 
our understanding of differential effects of atomic bomb 
irradiation on major leukemia types. 
(4) Age distribution 
 Fig. 2 summarizes the composition of the LSS cohort 
used for this study by age ATB, sex, and vital status at the 
end of follow-up on 31 December 1987. The cohort con-
tained a relatively large population of women (58.4 %) due 
to the relatively small number of males between the ages 
of 15 and 50 years as the results of the Warfare. Roughly 
two thirds of the survivors are Hiroshima cases. It is 
notable that there were over 16,000 children under age 10 
ATB and female preponderance in this cohort.
Fig. 2. LSS cohort : age ATB distribution by sex and vital 
status.
Fig. 1. Leukemia regisrtry for A-bomb survivors since 1950 
(Hiroshima and Nagasaki).
(2) Dosimetry of radiation exposure 
   in individual survivors 
 Dosimetry of bone marrow kerma employed in the two 
studies is the 1986 dosimetry system (DS86) which was 
improved from the previous dosimetry system DS65 by 
re-evaluation of gamma and neutron doses in both cities 
by taking into acounts of atomospheric influences such as 
humidity on radiation diminution.
Life Span Study 
(1) Analysis of all leukemia types combined 
 261 leukemia cases met the basic criteria for the analy-
sis. Among these cases, 231 with DS86 kerma estimates 
between 0 and 4 Gy were used for analysis. Background 
rates (expected rates in the absence of exposure) can be 
described by a model in which the log of the rate is a 
quadratic function of the log of attained age. The age-
specific rates for women are about half of those seen in 
men. There is a statistically significant exposure dose 
response (P<0.001) that appeared to be non-linear in dose 
(P<0.008) as indicated in Fig. 3. The hypothesis of a 
0.5-Sv threshold could be rejected (P<0.001). Young men
had high excess abosolute risk (EAR) in the period from 5 
to 10 years after exposure, but these risks decreased 
rapidly with time. The EAR for older men are not as high 
in the early years and declined more slowly than those for 
younger men. Women tended to have lower EAR than men 
until roughly 20 years after exposure. The data for older 
women suggest that the risks have not decreased with 
time.
risk (ERR) at 1 Sv was 9.1 and EAR was 0.62 per 10,000 
PYSv.
Fig. 4. LSS cohort : acute lymphocytic leukemia.
Fig. 3. LSS cohort : leukemia, all types. (A) Time since 
exposure. (B) Dose response.
(3) Acute Myeloid Leukemia (AML) 
 There were 103 eligible cases with DS86 doses between 0 
and 4 Gy. AML background rates in this cohort could be 
described by a model in which the log rate varied as a 
sex-dependent quadratic function of log attained age with 
an effect of birth cohort of 1910 and 1940. There was a 
strong evidence of a dose response (P<0.001) and a 
suggestion of non-linearity as indicated by tests based on 
either quadratic (P = 0.05) or spline models (P = 0.04). 
The 0.5-Gy threshold model did not fit these models (P = 
0.05). Thus AML dose response function was different 
from those for other leukemia subtypes (ALL and CML). 
As shown in Fig. 5 age at bombing had a significant effect 
on the EAR, with the youngest survivors having the 
highest average absolute risks. The model-based time-
averaged ERR is estimated to be 3.3. and the correspond-
ing EAR estimate is 1.1 cases per 10,000 PYSv.
(2) Acute Lymphocytic Leukemia (ALL) 
 Of the 38 ALL cases that met the basic criteria for 
including in the study, 32 had DS86 kerma estimates 
between 0 and 4 Gy. Because of the small number of cases 
and the relatively high percentage of cases with unkown 
dose, the analysis of effect modifying factors were supple-
mented by analyses that used survivors with unknown 
DS86. Background rates was roughly log linear in attained 
age. The test for a dose response was highly significant 
(P<0.001). Our final model for the ALL risk is a linear 
dose-response model in which the EAR has decreased 
rapidly with time, about 14% per year. As shown in Fig. 4 
children exposed under age 10 had the highest excess risks. 
For any age at bombing or time since exposure, the EAR 
estimates for women were estimated to be less than half 
those for men. Fig. 4 also shows plots of the EAR for men 
and women exposed to 1 Sv at the ages of 10, 25 and 40 
years. Confidence bands are shown only for males. The 
model-based summary risk estimates are. excess relative
Fig. 5. LSS cohort : acute myelogenous leukemia.
(4) Chronic Myeloid Leukemia (CML) 
 Of the 62 cases that were eligible, 57 had DS86 kerma 
estimates between 0 and 4 Gy. Backgroud rate is roughly 
proportional to attained age squared. Background rates 
differed significantly by sex (P = 0.008) with age-specific 
rates for women about 60% of those for men. As shown in
Fig. 6 the difference between cities was even more pro-
nounced (P = 0.003) with rates in Hiroshima for either sex 
being more than three times those in Nagasaki. The CML 
data are consistent with a linear nonthreshold dose-
response model. The hypothesis of a 0.5-Gy threshold could 
be rejected for these data (P = 0.003). The model based 
ERR was 6.2 and EAR 0.9 cases per 10,000 PYSv.
the test for type-specific differences in the shape of the 
dose-response function was not significant (P = 0.35). 
Although this test was not a powerful one, this result 
suggests that the differences in the shape of the dose-
response function decribed above should be interpreted 
with caution. There was strong evidence against 0.5-Gyz 
threshold (P = 0.001).
Fig. 6. LSS cohort : choronic myelogenous leukemia, (A) 
Backround rates. (B) Time since exposure/excess absolute 
risk model (1 Sv exposure). Fig. 7. LSS cohort : leukemia joint analysis (leukemia 
dose-response function).
(5) Joint analysis for ALL, AML and CML 
 The results of the above described type-specific leukemia 
analyses suggest that there are differences in the nature of 
the dose response for each leukemia type. These differences 
were summarized in Fig. 7 which compared the dose-
response curves for the four diagnostic subtypes (ALL, 
AML, CML and Other) considered above, 5 and 35 years 
after exposure for three groups of age at bombing. The 
joint analysis suggests that there are significant inter-
leukemia type differences in both the temporal pattern (P 
= 0.02) and the nature of the variation of the risk with 
age ATB (P = 0.002). After allowing for these differences 
a test for non-linearity in the dose response function, with 
a common amount of curvature for all three types as-
sumed, was statistically significant (P = 0.008), whereas
Open City Study 
(1) Leukemia classification and statistics 
 Since 1986 to 1991, we have attempted to review the 
hematological data and peripheral blood and bone marrow 
specimens archived at RERF and at several majour hospi-
tals in Hiroshima and Nagasaki in purpose of further 
clarifying the differential effects of atomic bomb irradia-
tion on the major subtypes of human leukemias by classi-
fying survivors' .leukemias according to the newly 
established FAB classification on acute leukemias and 
myelodysplastic syndromes (MDS), and newly recognized 
entities such as adult T-cell leukemia (ATL) which is an
virus-induced endemic disease in Nagasaki district. As 
shown in Fig 1, from 1950 through 1980, 766 cases of 
leukemia were registered from the Open City Sample, of 
which 249 occurred in the LSS cohort. We could reclassify 
493 (64.4%) cases including 177 LSS cases. Of these 
reclassified cases, 413 with estimated DS86 kerma were 
categorized for statistical analysis into four major types; 
ALL, AML including MDS, CML, and Other including 
ATL. 
 The type specific incidence rates were obtained by 
estimating the overall incidence of leukemia from the LSS 
data with a fixed cohort and multiplying these values by 
the corresponding proportions of cases in OCS. In this 
way, information relevant to our objectives was extracted 
from leukemia cases outside the LSS cohort. Since this 
proportional analysis does not allow direct statistical 
comparison between leukemia types, ratios of relative 
risks (RRR) was calculated to compare the effects of 
dose, age at bombing, city and latency period on the 
incidence of ALL, CML, and Other relative to their effects 
on the incidence of AML. AML was chosen as the reference 
type because it is the most prevalent of all leukemias. 
Statistical basis for the RRR analysis was decribed in 
detail in the RERF technical report (TR 9-91).
Fig. 8. Open City : incidence rate by age (age at time of 
bombing) leukemia type, dose and calendar years.
(2) Type-specific incidence 
 The incidence rates of all types of leukemia eventually 
increased with increasing exposure level in each age at 
bombing (ATB) category. The relative risks (RR) of 
radiation exposure (i.e., exposed=not exposed) were also
apparently elevated with increasing dose in all types of 
leukemia (data not shown). The effects of age at bombing 
were quite different between the types of leukemia. The 
RR was most markedly elevated in 0-15 age at bombing 
category for ALL. In this age group, the RR of ALL was 
apparently greater than those of CML and AML. Fig. 8 
illustrates temporal pattern of the elevated incidence rate 
of major three types of leukemia according to five expo-
sure dose categories and three age at bombing categories. 
The elevated incidences for ALL and CML declined rather 
quickly with time in < 15 age category especially of high 
dose categories, whereas that for AML was persistently 
elevated through 1976-80 period especially in the adult age 
categories especially of high dose categories. 
 Cases of ATL were observed only in Nagasaki. These 
cases make up 60% of the Other category. The highest 
incidence of ATL was observed in the high-dose category 
(>1000 mGy) in the early period, suggesting a radiation 
effects on ATL incidence. However, this might be random 
fluctuation and would not attain statistical significance 
because there were only two cases in the high dose category 
(data not shown). 
(3) Comparison of leukemia types 
 Although statistical methods for testing the effects of 
radiation exposure, age at bombing, city and period since 
exposure on type-specific incidence rates are not yet 
available, relative risk ratios (RRR) are used to compare 
leukemia types. This method could provide indirect statis-
tical evidence for the suggestive findings. RRR were 
calculated to compare the effects of A-Bomb radiation 
exposure on the incidence of ALL, CML and Other types 
relative to its effect on the incidence of AML as mentioned 
above. As shown in Table 1, for ALL and CML, these 
ratios are generally significantly > 1 (P = 0.05), even in 
the lowest exposure categories through 1956-1960 period (P 
= 0.05) , and become non-significant by 1966-70. This 
means that radiation exposure had a greater effects on the 
rates of CML and AML in early periods than that of AML. 
The effects of radiation on Other types did not differ 
significantly from its effect on AML at any time for all 
exposure levels. 
 The fact that RRR of ALL and CML relative to AML 
are significantly > 1 for the lowest dose category (1-49 
mGy) in the period 1950-65 provides statistically signifi-
cant evidence for the suggestion that exposures less than 
50 mGy produced excesses of ALL and CML. This state-
ment naturally presumes that low dose radiation did not 
have a protective effect against AML induction. RRR of 
CML relative to AML was 0.12 in the period 1976-80, 
suggesting statistical support for an excess of AML 
remained through 1980 in the highest dose category. The 
RRR of ALL relative to CML was 7.42, providing statisti-
cal support for the suggestion that an excess of ALL
Table 1. Ratios of relative risks1 for comparing exposure effects on acute lymphocytic (All), chronic myeloid (CML), and 
other leukemias (Other) to corresponding effects on acute myeloid leukemia (AML)'
 Leukemia Category Time period 
   typeb (mGy) 1945-50 1951-55 1956-60 1961-65 1966-70 1971-75 1976-80 
 ALL 0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
                1-49 10.92** 7.49** 5.14** 3.52* 2.42 1.66 1.14
              50-499 9.99** 5.82`* 3.39** 1.97 1.15 0.67 0.39
             500-1499 3.32 3.00** 2.70 * 2.44 2.20 1.98 1.78
                ? 1500 20.70** 12.25 7.25** 4.29** 2.54 1.50 0.89
 CML 0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
                1-49 12.10** 7.21** 4.30** 2.56* 1.53 0.91 0.54
                50-499 6.91** 5.82** 4.90** 4.12** 3.47** 2.92* 2.46
              500-1499 9.88 * * 6.97 * * 4.92 * * 3.47 * * 2.45 1.73 1.22
                ? 1500 11.68** 5.47** 2.56** 1.20 0.56 0.26 0.12*
 Other 0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
              1-49 0.14 0.20 0.30 0.45 0.67 1.00 1.49
             50-499 0.14 0.24 0.42 0.74 1.29 2.26 3.96 
             500-1499 2.44 1.52 0.92 0.59 0.37 0.23 0.14
               2; 1500 2.03 1.43 1.01 0.71 0.50 0.35 0.25
Other includes adult T-cell Leukemia and other specifically diagnosed leukemias. 
aRisk of different leukemia types at given exposure levels , relative to the nonexposed group, divided by thecorresponding 
relative risk of AML. Relative risk ratios >1.0 suggest a greater radiogenic effect on the given leukemia than on AML ; 
ratios<1.0 suggest a greater effect of the given level of radiation on AML risk. 
bIncluding myelodysplastic syndrome . 
*P<0 .10; **P<0.05
Table 2. Ratios of relative risks for city effects8 on background rates of leukemia
       City ALL CML Other AML 
      Hiroshima 1.00 1.00 1.00 1.00 
      Nagasaki 0.64 0.43* 2.65 * 1.00 
                            (0.31, 1.32)b (0.23, 0.79) (1.36, 5.17) 
ALL, acute lymphocytic leukemia ; AML, acute myeloid leukemia ; CML, chronic myeloid leukemia ; and Other, leukemia 
including abult T cell leukemia and other specifically diagnosed leukemias. 
'The risk of these leukemia types in Nagasaki
, relative to those in Hiroshima, divided by the corresponding relative risk of 
AML. 
bThe values within parentheses are the 95% confidence intervals . 
*P S0 .05
Table 3. Ratios of relative risks for age at the time of the bombings (ATB) effects` on background rates of leukemia
    ATB (years) ALL CML Other AML 
         0-15 1.00 1.00 1.00 1.00 
        16-35 0.40** 2.00* 1.65 1.00 
                            (0.18, 0.89) b (0.96, 4.17) (0.71, 3.55) 
         z 36 0.40** 1.93* 7.38* 1.00 
                           (0.18, 0.89) (0.91, 4.08) (1.16, 6.00) 
ALL, acute lymphocytic leukemia ; AML, acute myeloid leukemia ; CML, chronic myeloid leukemia ; and Other, leukemia 
including abult T cell leukemia and other specifically diagnosed leukemias. 
(Risk of leukemia types in each ATB category , relative to the risk in the 0-15-year-old category, divided by the corresponding 
relative risk of AML. 
bThe values with parentheses are the 95% confidence intervals . *P<0 .10; **P<0.05.
remained through 1980. 
 As shown in Table 2, the RRR for city effects on back-
ground rates of leukemia were marked in CML and Other : 
estimated risk of CML in Nagasaki relative to Hiroshima 
was significantly less than that of AML, whereas that of 
Other types (mainly ATL) was sigificantly greater. 
Because there is no consistent difference in relative risks 
between cities, the city effect on background rates appear 
to explain a generally higher incidence (except for ATL) in 
Hiroshima than in Nagasaki. 
 As showm in Table 3, ratios of the incidences of each 
leukemia type in 16-35 and >35 relative to that in the 
youngest age at bombing (0-15) were calculated. ALL was 
induced at the highest rate in children, whereas CML and 
AML were induced at the highest rates in older adults. 
(4) AML subtypes and exposure levels. 
 The distribution of AML subtypes in the the lower 
exposure categories (0-9 mGy, and 10-999 mGy) does not 
seem to differ greatly from that in the current general 
population in Japan (data not shown). The distribution in 
the highest category (> 1000 mGy) was 5 cases (29.4%) 
for M1, 6 cases (35.3%) for M2, none for M3, 4 cases 
(23.5%) for M4, and one case (5.9%) each for M5 and M6. 
There is a suggestion that M3 is less radiogenic than M1, 
M2, and M4, but the statistical evidence is not sufficient 
to support such a conclusion (0.06<P<0.12). 
(5) MDS 
 There were 26 cases of MDS, mostly refractory anemia 
with excess of blasts (RAEB). These were diagnosed 
mainly as AML in the previous LSS Study. RRR of MDS 
relative to AML was significantly >1, suggesting that 
MDS is more radiogenic than AML (P = 0.04). Most cases 
of MDS were more than 20 years age at bombing and only 
two cases under age 20. They developed the disease after a 
relatively long latency (data not shown).
Fig. 9. Relationship of time since exposure to onset and 
dose.
(6) Dose and latency according to leukemia types 
 The relationship between dose and time to onset varied 
significantly among leukemia types as shown in Fig. 9. 
With increasing dose, the times to onset of ALL, AML, 
and CML all declined siginificantly. However, the rate of 
decline was significantly greater for ALL and CML than 
for AML and Other (P<0.05).
Discussion 
 The statistical analysis based on LSS data generated 
from a fixed RERF's cohort of survivors and OCS analysis 
based on leukemia cases detected in the general population 
of survivors provided basically similar results concerning 
the incidences of leukemia types, their dose responses, 
effects of age at bombing, latency periods, and temporal 
patterns of the elevated risks. Thus, we could utilize fully 
all available data on leukemias which have been known as 
the major late effect of atomic bomb irradiation. The 
principal finding of this comprehensive analyses was that 
the risk associated with radiation exposure varied signifi-
cantly among major types of leukemia. In this respect 
summary risk analysis by combining all types of leukemia 
can be misleading. Risk estimator such as dose response, 
age at bombing, latency period and lesser extent, sex were 
all dependent on leukemia types. All these results proved 
importance of reclassification work which allowed us to 
review atomic bomb irradiation-induced leukemias in the 
light of the present knowledge on types of human leuke-
mia. 
 The present analysis also emphasizes the importance of 
allowing for the background incidence rates when assessing 
radiation-induced leukemia risks. In particular, it is 
essential to recognize the difference between Hiroshima 
and Nagasaki for CML and ATL baseline rates when 
interpreting the data on excess risks for these subtypes. 
Earlier mis-understanding of the nature of the excess risks 
for the two cities (CML risk was much higher in 
Hiroshima than in Nagasaki) arose because inter-city 
differences in the backgroud rates were not considered. The 
present analysis clearly demonstrated that the EAR for 
CML is higher in Hiroshima than in Nagasaki because of 
the difference in the background rates and the ERR was 
actually identical between two cities. However, the differ-
ence in the background rate for CML remains as an enigma 
to be answered in future bacause it is generally believed 
that annual incidence of CML in Japan as well as in the 
world is rather constant and no geographic deviation has 
been so far reported. 
 Among major three types of leukemia associated with 
radiation exposure, ALL and CML (at least for males) 
showed higher ERR than AML and share similar responses 
characterized by a linear, non-threshold dose response and
an initial high risk followed by a gradual decline. In 
contrast AML dose response was non-linear. Inspite of this 
difference, our results suggested that there are detectable 
excess risks for all types of leukemia at doses below 0.5 
Gy. OCS data suggested such excess risks for ALL and 
CML even in the lowest (< 50 mGy) dose categories. 
Although LSS results are not at all inconsistent with those 
of OCS, the risks at this very low doses was much lower 
than in the latter study. Since OCS has an inherent limit 
for statistical consistency due to its indirect method, we 
need to reserve final conclusion on the effect of extremely 
low dose of A.Bomb irradiation in inducing leukemias. In 
other words, this situation seems to reflect a statistical 
limit derived from the sample size which was determined 
in 1950 when LSS was started. Unfortunately the LSS 
sample size seemingly large enough for statistical analysis 
of common malignancies was rather small for relatively 
rare diseases such as leukemia. In conclusion the existence 
of threshold dose for the induction of human leukemia 
could not be firmly established by the present comprehen-
sive analysis. If it existed, it would be a dose lower than 
0.5 Gy in all types of leukemia. 
 The risk for AML decreased with time for younger 
survivors but remained stable or possibly increased over 
decades for older survivors. This is a sharp contrast to the 
early onset and gradual decline of the risks for ALL and 
CML in childhood exposure group. Although the latency 
period was apparently dependent on exposure dose in all 
types of leukemia, that of AML was extremely long 
compared with those of ALL and CML. This might be a 
reflection of the differnce in undergoing leukemogenic 
processes which eventually lead to either type of leukemia. 
The temporal pattern for AML among survivors exposed 
as adults resembles that which has generally been found 
for solid tumor incidences. The separate analysis for MDS 
in OCS also suggested a similar trend in temoral pattern. 
In this respect, it is important to continue follow up study 
on the survivors exposed at young age at bombing who are 
now passing through their cancer-prone age. 
 The reclassification analysis of OCS sample suggested 
that it was not difficult to classify atomic bomb survi-
vors' leukemias according to the new modern classification 
systems. The observed morphologies of AML and ALL 
cases among high-dose exposure groups were basically 
similar to those of de novo (spontaneous) leukemias that 
develope in the non-exposed population of either city and 
in the general population of Japan. A fairly large number 
of MDS cases, mostly RAEB, were also recognized, and 
these were also similar to de novo MDS. Subclassification 
of AML and ALL cases was also not difficult according to 
FAB classification. It was, however, notable that there 
was no case of M3 in the high dose group. It has been 
frequently reported that secondary or therapy-related 
leukemia/MDS which is another exmple of human leu-
kemias with an apparent etiology (anti-cancer drugs), are
somewhat different in clinical and morphological picture 
from de novo leukemias and MDS. It is also true that CML 
and ALL rarely occur as therapy-related leukemia'). In this 
context it may be notable that the atomic bomb survivors' 
leukemias, induced by a single massive irradiation,are 
closer to spontaneous leukemias from a morphological 
point of view. 
 The prototype leukemia was ALL in those survivors 
exposed in their childhood. Although there were also excess 
risks for AML and CML, these were less prominent than 
that for ALL. It is a general rule that ALL is exclusively 
dominant in de novo leukemias of childhood. This age-
specific dominance of ALL was clearly reproduced in the 
childhood exposure groups in the early period after bomb-
ing, suggesting that atomic bomb irradiation might have 
augumented ALL-leukemogenesis which seems to be 
operating in the general population of children. In order to 
further prove this hypothesis, we need to start molecular 
investigation on the paraffin-embedded materials such as 
spleen and bone marrow obtained from autopsied cases of 
various types of leukemia, since we are now recognizing 
molecular heterogeneity in ALLs diagnosed according to 
FAB system. Special reference to molecular detection of 
bcr/abl gene rearrangement which is an eqivalent of 
cytogenetic Philadephila translocation, is needed to clarify 
whether childhood ALL among heavily exposed survivors 
are Philadelphia translocation-positive or not. It is 
generally accepted that de novo childhood ALL usually 
lacks Philadelphia translocation but adult ALL shows 25 
to 30% positive rate. Also it is notable that most of the 
bcr/able rearrangement are minor type in de novo ALL in 
contrast to the virtually 100% incidence of major type 
bcr/abl in CML. 
 Long latency for the induction of AML and MDS and its 
persistently elevated risks in the adult exposure groups, 
also raise some interesting questions. It is difficult to 
exlain such a long latency by a single genetic event induced 
by radiation which leads to occurrence of AML. There are 
consistent evidences for chromosomal injury in multi-
potent hematopoietic stem cells of heavily-irradiated 
survivors. We need to suspect multistep leukemogenic 
factors or events occurring in such wounded stem cells 
which survive over many years after exposure to radiation 
but eventually transform. A number of oncogenes and 
anti-oncogenes have been found to be closely related to 
pathogenesis of various subtypes of de novo AML and 
MDS. In this respect molecular analysis is also essential to 
make clear the relationship between atomic bomb-related 
AML and de novo AML. 
 To solve these interesting questions we need to analyse 
molecularly the leukemia materials such as paraffin-
embedded bone marrow and spleen specimens archived at 
RERF or universities. It is absolutely necessary to prove 
or disprove that atomic bomb irradiation-induced leu-
kemias are genetically similar to de novo leukemias. Such
a molecular technique to identify oncogenes and anti-
oncogenes is now under development although it is a hard 
task to extract enough DNA or RNA from the 30 to 40 
years old specimens'). 
 As summarized above, 50 years' long term follow up 
study on leukemia among atomic bomb survivors provided 
tremendous amounts of information concerning human 
leukemogenesis. The bone marrow hematopoietic tissue 
exposed to significant dose of radiation usually lose 
hematopoietic activity due to damage to stem cells. 
However, the bone marrow usually recover after a few 
months without obvious abnormality of blood cells. There 
are a few important studies which suggest that the target 
cells of radiation injury are hematopoietic stem cells". 
However, it is still obscure whether these target cells were 
directly injured of their genome or reduction in number of 
stem cells by radiation injury eventually induced abnor-
malities in genome of a stem cell as a result of enhanced 
genetic error by increased cell cycle. In an animal experi-
ment using canine showed that a profound reduction in 
stem cell number precedes the occurrence of leukmia in 
irradiated dogs'). Similar reduction was also reported in 
cases of survivors from Bikini hydrogen bomb experiment, 
although there was no leukemia occurence in this small 
population'. 
 In conclusion our understading of radiation leukemo-
genesis as a model of human carcinogenesis has advanced 
considerablly owing to the 50 years-long term survey on 
leukemia among atomic bomb survivors. To further extend 
our knowledge and obtain therapeutic hint we need un-
doubtedly an further advance in molecular epidemiology.
Aknoledgement 
 The authors express their sincere thanks to all people 
who were engaged in this leukemia study program (HE39).
References 
1) Court Broun WM, Doll R : Mortality from cancer and other causes 
   after radiotherapy for ankylosing spondylitis. Br Med J 2 : 1327, 1965 
2) Ishimaru T, Hoshino T, Ichimaru M, Okada H, Tomiyasu T, 
   Tsuchimoto T, Yamamoto T : Leukemia in atomic bomb survivors, 
   Hiroshima-Nagasaki, 1 Oct 1950-30 Sep 1966. Rad Res 45: 216, 1971 
3) Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, 
   Kamada N, Dohy H, Matsuo T, Nonaka H, Thompson DE, Soda M, 
   Mabuchi K : Cancer incidence in atomic bomb survivors. Part III : 
   leukemia, lymphoma and multiple myeloma, 1950-1987. Rad Res 137: 
  s68, 1994 
4) Tomonaga M, Matsuo T, Carter RL, Bennett JM, Kuriyama K, 
   Imanaka F, Kusumi S, Mabuchi K, Kuramoto A, Kamada N, 
   Ichimaru M, Pisciotta AV, Finch SC : Differential effects of atomic 
   bomb irradiation in inducing major leukemia types (AML, ALL and 
   CML) : Analysis based upon up-dated diagnostic systems and new 
   dosimetry system (DS86). TR9-91, Radiation Effects Research 
   Foundation, Hiroshima, 1991 
5) Michels SD, Mckenna RW, Arthur DC, Brunning RD: Therapy-related 
   acute myeloid leukemia and myelodysplastic syndrome : A clinical 
   morphologic study of 65 cases. Blood 65: 1364, 1985 
6) Aure I, Juhbashi T, Sekine M, Tomonaga M, Gale RP : Analysis of 
   bcr/abl abnormalities in mRNA from 20-year-old paraffin-embed-
   ded tissue for bcr/abl rearrangement by polymerase chain reaction. 
   Acta Haematol 90: 5, 1993 
7) Amenomori T, Honda T, Otake M, Tomonaga M, Ichimaru M : 
   Growth and differentiation of circulating hematopoietic stem cells
   with atomic bomb irradiation-induced Chromosome abnormalities. 
   Exp Hematol 16: 849, 1988 
8) Seed TM: Hematopoietic cell crisis : an early stage of evolving myeloid 
   leukemia following chronic radiation exposure. J Rad Res 32 (Suppl 2): 
  118, 1991 
9) Hirashima K, Sugiyama H : The 1971 Chiba, Japan accident : exposure 
   to iridium 192. The medical basis for radiation accident preparendness 
   (Hubner KF and Fry SA, ed.), Elsvier North Holland, New York, 
   179-195,1980
